The limited capability in most low-to middle-income countries to study the benefit of pneumococcal conjugate vaccine (PCV) in protecting against invasive pneumococcal disease (IPD) calls for alternate strategies to assess this. We used a mathematical model to predict the direct and indirect effectiveness of PCV by analyzing serotypespecific colonization prevalence and IPD incidence prior to and following childhood PCV immunization in South Africa. We analyzed IPD incidence from 2005 to 2012 and colonization studies undertaken in human immunodeficiency virus (HIV)-uninfected and HIV-infected child-mother dyads from 2007 to 2009 (pre-PCV era), in 2010 (7-valent PCV era), and in 2012 (13-valent PCV era). We compared the model-predicted changes in IPD incidence with observed changes in IPD incidence, according to HIV status, in children aged 3 months-5 years and in women aged 18-45 years. We observed reductions in vaccine-serotype colonization and IPD due to vaccine serotypes among children and women after PCV introduction. Using the changes in vaccine-serotype colonization data, the model-predicted changes in vaccine-serotype IPD incidence rates were similar to the observed changes in PCVunvaccinated children and adults, but not among children under age 24 months. Surveillance of colonization prior to and following PCV use can be used to impute the indirect protection afforded by PCV in unvaccinated age groups, including those in high-HIV-prevalence settings.
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The limited capability in most low-to middle-income countries to study the benefit of pneumococcal conjugate vaccine (PCV) in protecting against invasive pneumococcal disease (IPD) calls for alternate strategies to assess this. We used a mathematical model to predict the direct and indirect effectiveness of PCV by analyzing serotypespecific colonization prevalence and IPD incidence prior to and following childhood PCV immunization in South Africa. We analyzed IPD incidence from 2005 to 2012 and colonization studies undertaken in human immunodeficiency virus (HIV)-uninfected and HIV-infected child-mother dyads from 2007 to 2009 (pre-PCV era), in 2010 (7-valent PCV era), and in 2012 . We compared the model-predicted changes in IPD incidence with observed changes in IPD incidence, according to HIV status, in children aged 3 months-5 years and in women aged 18-45 years. We observed reductions in vaccine-serotype colonization and IPD due to vaccine serotypes among children and women after PCV introduction. Using the changes in vaccine-serotype colonization data, the model-predicted changes in vaccine-serotype IPD incidence rates were similar to the observed changes in PCVunvaccinated children and adults, but not among children under age 24 months. Surveillance of colonization prior to and following PCV use can be used to impute the indirect protection afforded by PCV in unvaccinated age groups, including those in high-HIV-prevalence settings.
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Nasopharyngeal colonization by Streptococcus pneumoniae precedes pneumococcal disease; hence, serotypes identified in invasive pneumococcal disease (IPD) are mostly identical to those in the nasopharynx at the time of illness (1) (2) (3) . Children vaccinated with pneumococcal polysaccharide-protein conjugate vaccine (PCV) have an approximately 50% reduced risk of acquisition of vaccine-serotype nasopharyngeal colonization compared with unvaccinated children (4) . Since young children are the main source of transmission of pneumococcus (1) , targeted PCV immunization of children has interrupted transmission of vaccine serotypes within communities (5) . Consequently, a reduction in the prevalence of vaccineserotype nasopharyngeal colonization has also been described among PCV-unvaccinated individuals at the household and community levels (5) (6) (7) (8) (9) (10) .
Concurrently, a decline in the incidence of vaccine-serotype IPD among PCV-vaccinated and -unvaccinated individuals has been observed, along with reductions in colonization (11) (12) (13) . In the United States, the indirect effect of childhood PCV immunization has resulted in the prevention of 2-to 10-fold greater numbers of IPD cases among PCV-unvaccinated adults than among the childhood age groups targeted for vaccination (11, 14) . There is a paucity of data from low-to middle-income countries, mainly due to the lack of robust IPD surveillance systems for assessing the effectiveness of childhood PCV immunization in protecting against IPD among PCV-unvaccinated age groups (15, 16) . Such information could help improve the public health benefit and costeffectiveness of childhood PCV immunization. Weinberger et al. (17) proposed that ecological studies on nasopharyngeal vaccine-serotype and non-vaccine-serotype colonization prior to and following the introduction of childhood PCV immunization may be useful for imputing the direct and indirect effectiveness of vaccination against IPD, which was validated in high-income and low-human immunodeficiency virus (HIV)-prevalence settings.
Our aim in this study was to analyze the direct and indirect effects of infant PCV immunization on nasopharyngeal colonization and IPD among HIV-infected and HIV-uninfected children and women in Soweto, Johannesburg, South Africa. Furthermore, we evaluated the fit of the model proposed by Weinberger et al. (17) to determine whether temporal changes in vaccine-serotype colonization relative to childhood PCV immunization were predictive of the direct and indirect effects of PCV against IPD.
METHODS

Study population
A series of pneumococcal colonization studies were undertaken among mother-child pairs in Soweto (Johannesburg, Gauteng Province, South Africa), a township with a population of 1.8 million, of whom 160,000 are under 5 years of age (Gauteng subdistrict population midyear estimates for 2005-2012; Andy Valashiya, South Africa Department of Health, unpublished data, 2013). We enrolled HIV-infected and HIVuninfected children aged 3 months-5 years and their mothers aged 18-45 years. We specifically targeted the mothers of the children, since in our setting women have greater contact with children than men, which may contribute to their having a higher incidence of IPD (particularly IPD due to 7-valent PCV (PCV7) serotypes) than men (18) . The prevalence of HIV among pregnant women (29%-30%) and those aged 15-49 years (20%) has remained stable in the community since 2005 (19) . However, the rate of mother-to-child HIV transmission had declined from 8% in 2008 to 1.5% by 2012 (20) .
During the study period, more than 90% of the Sowetan population sought medical care at Chris Hani Baragwanath Hospital. Although numbers of community deaths are not known, the presence of a good transport network and the provision of free health care mean that there are few deaths in the community (Shabir A. Madhi, University of the Witwatersrand, unpublished data, 2014). The effectiveness of infant PCV immunization against IPD in this community was included in a recent national analysis of IPD trends in South Africa in relation to the introduction of PCV into the national immunization program (21) . This study provides information on temporal changes in the incidence of IPD in children and women from Soweto.
Details on the introduction of PCV into the South African immunization program have been previously provided (22) and are included in the Web Appendix (available at https:// academic.oup.com/aje). Briefly, PCV is given at ages 6 and 14 weeks in South Africa, with a booster dose at age 9 months.
Pneumococcal colonization studies in Soweto (2007) (2008) (2009) (2010) (2011) (2012) Prior to introduction of PCV7, we undertook a longitudinal cohort study to investigate the dynamics of pneumococcal transmission in HIV-uninfected mother-child pairs between January 2007 and April 2009 (pre-PCV era) (23) . Briefly, the study showed an association of vaccine serotype acquisition between young children and their mothers (24) , with children transmitting PCV7 serotypes to their mothers more often than vice versa (23) . Subsequently, 2 cross-sectional colonization prevalence surveys carried out in mother-child pairs with concordant HIV status were undertaken in the same population in 2010 (PCV7-era) and 2012 (PCV13-era), as described elsewhere (22) . We demonstrated a reduction of PCV7-serotype colonization regardless of HIV status in mothers and their children, with a concomitant increase in non-vaccineserotype colonization in children but not in the mothers between 2010 and 2012 (22) . We transformed longitudinal data into cross-sectional data by randomly selecting a single visit for each mother-child pair that participated in the longitudinal study.
In the colonization studies, nasopharyngeal swabs were collected in children and nasopharyngeal and oropharyngeal swabs were collected from the mothers. The methods of laboratory processing and serotyping have been previously described (7); details are included in the Web Appendix.
IPD surveillance (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) Nationwide laboratory-based surveillance for IPD, including surveillance at Chris Hani Baragwanath Hospital, has been previously described (21) . Details are provided in the Web Appendix.
Statistical analysis
PCV7 serotypes were defined as any of the following: 4, 6B, 9V, 14, 18C, 19F, and 23F. The additional serotypes included in PCV13 (i.e., serotypes 1, 3, 5, 6A, 7F, and 19A) were categorized as PCV13-additional serotypes. Additionally, we analyzed serotype 6A separately to investigate cross-protection from serotype 6B. All non-PCV13 serotypes were categorized as nonvaccine serotypes. Nonviable isolates were prorated on the basis of identified serotypes, based on their similarity of distribution when analyzed by polymerase chain reaction (25) .
Incidence of IPD among children aged 3 months-2 years and 2-5 years and women aged 18- the pre-PCV-era incidence and was compared with that observed in 2010 and 2012; the percentage change and absolute differences were calculated. The 95% confidence interval, constructed using a Poisson distribution and testbased methods (26) , was used to evaluate the significance of the observed changes in IPD. The χ 2 test was used to assess differences in proportions. Since HIV prevalence among IPD cases in years prior to 2008 may have been underestimated because of a lower proportion of cases' having been tested for HIV (70% in 2005 vs. >88% in 2012), we used a previously developed method to account for this potential bias (21) .
Colonization prevalence was compared in the different study periods according to HIV status (22) . Colonization prevalence before and during the PCV eras (for adults, limited to women only) were used to estimate the colonization prevalence ratio (i.e., carriage postvaccine divided by carriage prevaccine; see Web Appendix) through the use of a weighted regression model proposed by Weinberg et al. (17) . The estimated prevalence ratio was then used to calculate the expected IPD incidence post-PCV introduction. We predicted IPD incidence for all serotypes, PCV7 serotypes, PCV13-additional serotypes, and nonvaccine serotypes based on the changes in observed prevalence of pneumococcal colonization for these serotype groups between the pre-PCV era and 2010 and 2012. This was undertaken for HIV-uninfected children aged 3 months-2 years and for HIV-infected and HIV-uninfected women aged 18-45 years. For HIV-infected children aged 3 months-2 years and for children aged 2-5 years, regardless of HIV status, in whom pre-PCV colonization data were unavailable, the predicted incidence of IPD using colonization prevalence in 2010 (PCV7 era) was compared with observed incidence in 2012 (PCV13 era). Prorating of nonviable serotypes was not possible in the model; therefore, we only predicted disease changes due to viable serotypes, and we compared these with observed IPD changes that were due to viable serotypes only.
Ethics
The Human Research Ethics Committee at the University of the Witwatersrand approved all components of this study. Informed written consent was obtained from participants in the colonization studies.
RESULTS
Temporal changes in pneumococcal colonization among children
Compared with the pre-PCV era, there was a reduction in the prevalence of both PCV7-serotype colonization and PCV13-additional-serotype colonization among HIV-uninfected children aged 3 months-2 years in 2012 ( Figure 1A and Web Table 1 ). Among these children, colonization prevalence between the pre-PCV era and 2012 decreased from 66.4% to 56.6% (odds ratio (OR) = 0.66, 95% confidence interval (CI): 0.44, 0.98) for all serotypes, from 30.4% to 9.6% (OR = 0.24, 95% CI: 0.16, 0.38) for PCV7 serotypes, and from 10.4% to 4.2% (OR = 0.38, 95% CI: 0.19, 0.73) for PCV13-additional serotypes. Notably, a trend towards a decline in PCV7-serotype colonization in this age group, particularly HIV-uninfected children, was already evident within 1 year of PCV7 introduction (OR = 0.72, 95% CI: 0.46, 1.12).
In contrast, colonization prevalence due to PCV13-additional serotypes between the pre-PCV era and 2010 was similar (10.4% vs. 13.5%; OR = 1.34, 95% CI: 0.71, 2.54), decreasing to 4.2% 1 year after PCV13 introduction. Compared with the pre-PCV era, the prevalence of non-vaccineserotype colonization increased from 25.6% to 42.9% by 2012 (OR = 2.18, 95% CI: 1.42, 3.34) ( Figure 1A and Web Table 1 ).
Pneumococcal colonization in women
Overall, the prevalence of pneumococcal colonization in women was 19.9% in the pre-PCV era. Prevalence in women decreased to 15 Table 1 ). PCV7-serotype colonization remained unchanged between the pre-PCV era and 2010 (4.0% vs. 3.9%) but declined to 0.7% in 2012 (OR = 0.18, 95% CI: 0.06, 0.57) among HIV-uninfected women, while in HIVinfected women it decreased from 10.3% in the pre-PCV era to 5.3% in 2010 (OR = 0.48, 95% CI: 0.25, 0.94) and 2.5% in 2012 (OR = 0.22, 95% CI: 0.10, 0.47). There was a trend towards reduced colonization with PCV13-additional serotypes, from 3.2% in the pre-PCV era to 1.5% in 2010 (OR = 0.46, 95% CI: 0.14, 1.48) and 1.3% in 2012 (OR = 0.39, 95% CI: 0.12, 1.22), in HIV-uninfected women, but colonization remained unchanged in HIV-infected women (range, 2.3%-3.3%). There was a decline in non-vaccine-serotype colonization among HIV-uninfected women between the pre-PCV era (15.2%) and 2012 (7.7%; OR = 0.47, 95% CI: 0.27, 0.80) and a nonsignificant increase in colonization with nonvaccine serotypes among HIV-infected women (4.8% in the pre-PCV era vs. 9.0% in 2012; OR = 1.99, 95% CI: 0.84, 4.73) (Web Table 1 ).
Changes in IPD incidence
IPD in children. Overall trends in IPD incidence for children aged 3 months-2 years and 2-5 years are reported in the Web Appendix and Web Table 2 .
Among HIV-uninfected children aged 3 months-2 years, the annual incidence (per 100,000 children of that age) of PCV7-serotype IPD had decreased by 84.9% by 2010 (from 68.6 in the pre-PCV era to 10.3; P < 0.001) and by 96.4% by 2012 (from 68.6 in the pre-PCV era to 2.5; P < 0.001) (Figure 2A and Web Table 2 ). Similarly, among HIV-uninfected children aged 2-5 years, the incidence of PCV7-serotype IPD had declined by 83.3% by 2010 (from 8.6 in the pre-PCV era to 1.4; P = 0.016), while no PCV7-serotype IPD cases were recorded in 2012 (100% reduction; P < 0.001) ( Figure 2C and Web Table 2 ). The incidence of IPD attributable to PCV13-additional and nonvaccine serotypes remained unchanged for both childhood age groups between the pre-PCV era and 2012.
Among HIV-infected children aged 3 months-2 years, the incidence (per 100,000) of PCV7-serotype IPD had declined by 62.4% by 2010 (from 1,341 in the pre-PCV7 era to 504.7; P = 0.001) and by 86.1% by 2012 (from 1,341 in the pre-PCV7 era to 184.4; P < 0.001) ( Figure 2B and Web Table 2 ). Furthermore, the incidence (per 100,000) of IPD attributable to PCV13-additional serotypes declined from 268.2 in the pre-PCV era to 63.1 in 2010 (P = 0.055), while no cases were observed in 2012 (100% reduction; P = 0.009). The incidence of non-vaccineserotype IPD remained unchanged among HIV-infected children aged 3 months-2 years between the pre-PCV era and 2012. Among older (ages 2-5 years) HIV-infected children, PCV7-serotype IPD incidence (per 100,000 children of that age) declined from 389.0 in the pre-PCV era to 244.7 in 2010 (a 37.1% reduction; P = 0.124) and 38.9 in 2012 (a 90% reduction; P = 0.061), though this change was not statistically significant ( Figure 2D and Web Table 2 ). Similar to the case with HIV-uninfected children, the incidence of PCV13-additional serotypes and non-vaccine-serotype IPD was unchanged between the pre-PCV era and 2012.
IPD in women of childbearing age. Among HIV-uninfected women of childbearing age (ages 18-45 years), the annual incidences (per 100,000 women of that age) of IPD attributable to all serotypes, PCV7 serotypes, PCV13-additional serotypes and nonvaccine serotypes were 114, 43, 48, and 21, respectively, in the pre-PCV era ( Figure 2E , Web Appendix, and Web Table 3 ). The incidence of PCV7-serotype IPD subsequently declined by 63.9% by 2010 (P = 0.016), while no PCV7 cases were observed in 2012 (a 100% reduction; P < 0.001). Similar declines (84.0%) were observed in the incidence of PCV13-additional IPD (P = 0.001), while incidence of non-vaccineserotype IPD remained the same between the pre-PCV era and 2012 (1.1 vs. 0.4; P = 0.076).
The incidences (per 100,000) of IPD attributable to all serotypes, PCV7 serotypes, PCV13-additonal serotypes, and nonvaccine serotypes in HIV-infected women were 1,216, 388, 428, and 332, respectively, in the pre-PCV era ( Figure 2F and Web Table 3 ). The incidence of PCV7-serotype IPD had declined by 42.1% (P < 0.001) by 2010 and by 83.1% by 2012 (P < 0.001). Similarly, there was a 26.7% reduction in PCV13-additional-serotype IPD between the pre-PCV era and 2010 (109.2 per 100,000 women aged 18-45 years vs. 80.0 per 100,000; P = 0.004), with a further decline by 2012 (67.6% in comparison with the pre-PCV era; P < 0.001) ( Figure 2F and Web Table 3 ). A more modest decline in incidence (per 100,000) of non-vaccine-serotype IPD, from 84.7 in the pre-PCV era to 59.9 in 2012 (29.2%; P = 0.005), was detected.
The incidence of serotype 6A IPD was unchanged for both HIV-infected and HIV-uninfected individuals during the study period.
Evaluation of a model using temporal nasopharyngeal colonization data to predict IPD incidence
Model results in children. Among HIV-uninfected children aged 3 months-2 years, the model underestimated the decline in all-serotype IPD (viable serotypes only) between the pre-PCV7 era and 2012 (91.7% observed vs. 53.5% predicted; Web Figure 1A) , and similarly for both PCV7-serotype IPD (98.7% observed vs. 72.1% predicted; Web Figure 1C ) and PCV13-additional-serotype IPD (91.9% observed vs. 62.2% predicted; Web Figure 1E overlapping 95% confidence intervals for the latter (Table 1) . Similar results were obtained for all-PCV13-serotype IPD (Web Figure 2A) . For the viable non-vaccine-serotype IPD, the observed reduction was 64.0%, whereas the model predicted a significant 44.9% increase (Web Figure 2C and Table 2 ). Similar trends were observed when comparing the pre-PCV era with 2010. In older HIV-uninfected children (ages 2-5 years), who were unvaccinated with PCV at the 2010 nasopharyngeal sampling time point (PCV having been introduced into the World Health Organization's Expanded Program on Immunization in 2009, with no catch-up campaign), the model underestimated the observed decline in PCV7-serotype IPD (100% observed vs. 36.8% predicted; Web Figure 1C ). The wide confidence interval for PCV13-additional and nonvaccine serotypes did not permit further comparison of the observed and predicted changes in this age group (Web Figures 1E and 2C , Table 2 ).
Model results in women. Among HIV-uninfected women, comparing the pre-PCV era with 2012, the observed reduction in all-serotype IPD (93.1%) was higher than the modelpredicted estimate (79.8%) (Web Figure 1B and Table 1 ). Observed reductions were also higher for PCV7-serotype IPD (100% vs. 88.8%; Web Figure 1D ) and PCV13-additional serotypes (96.4% vs. 69.9%; Web Figure 1F model estimates. Similar results were obtained for all combined PCV13-serotype IPD (Web Figure 2B) . However, observed and model estimates were similar for non-vaccineserotype IPD reductions (79.0% vs. 78.8%; Web Figure 2D ). Similarly, among HIV-infected women, when comparing the pre-PCV era with 2012, the model-predicted estimates slightly underestimated the observed reductions in IPD for all serotypes (86.2% observed vs. 73.0% predicted; Figure 2B ) and PCV7 serotypes (94.5% observed vs. 80.0% predicted; Web Figure 1D ), but the model-predicted estimates were similar to observed reductions in IPD attributable to nonvaccine serotypes (72.5% observed vs. 72.6% predicted; Web Figure 2D) . The model-predicted estimate of the reduction in IPD attributable to PCV13-additional serotypes from 2010 to 2012 was lower than the observed reduction (67.9% observed vs. 31.4% predicted) (Table 1, Web Figure 1F) . Overall, the differences between model predictions and observed changes were small for children aged ≥2 years and adults but very large for children below 2 years of age.
DISCUSSION
Our study suggests that the introduction of PCV into the South African immunization program resulted in a reduction in the incidence of vaccine-serotype IPD among HIV-infected and HIV-uninfected children under 5 years of age and adults aged 18-45 years, which was also reflected by changes in pneumococcal nasopharyngeal colonization (22) . In our setting, which has a high prevalence of HIV that is associated with an 8.2-fold increased risk of IPD among adults (27) , we demonstrated that measuring temporal trends in nasopharyngeal colonization in relation to introduction of PCV into the public immunization program could be used as a proxy to determine the likely association of PCV with IPD among HIVinfected and HIV-uninfected women. This was evident from the magnitude of a model-predicted reduction in vaccineserotype IPD being similar to the observed reductions in adults, as well as child age groups too old to have been vaccinated. However, in the child age group targeted for vaccination, especially if children were HIV-uninfected, using changes in the prevalence of nasopharyngeal pneumococcal colonization to estimate the contribution of PCV to decreases in vaccineserotype IPD underestimated its effectiveness. This was most likely due to the model's not accounting for the direct efficacy of PCV in preventing vaccine-serotype IPD in this age group, which is mediated through humoral immunity that is more efficacious in preventing vaccine-serotype IPD than nasopharyngeal colonization (28) . The observed and model-predicted reductions in IPD were similar in PCV-unvaccinated females aged 18-45 years when comparing the pre-PCV era with the PCV7 and PCV13 eras. This was evident among HIV-uninfected and HIV-infected women, the latter of whom had a higher prevalence of pneumococcal (including vaccine-serotype) colonization (18, (29) (30) (31) (32) and IPD incidence in the pre-PCV era (21) . Because the model estimates were similar to observed reductions in IPD incidence, this suggests that the decrease in IPD after introduction of vaccine was a result of decreases in the prevalence of colonization with vaccine serotypes, likely through an interruption of transmission of these serotypes by vaccinating young children (12) .
The direct and indirect associations of PCV with IPD incidence observed in our setting are similar to those initially observed in the United States, where childhood PCV7 immunization reduced the incidence of vaccine-serotype IPD among the vaccinated children as well as older PCV-unvaccinated age groups, such as the high-risk elderly (11, 12, 33) . In our population, the decrease in IPD among persons aged 19-45 years represents a potentially significant public health benefit of infant PCV immunization, as this adult age group has the highest prevalence of HIV in South Africa (20) . Similar to the case elsewhere, the reductions in vaccine-serotype IPD among the HIVuninfected adults in South Africa (21) are most likely attributable to the indirect associations of infant PCV immunization reducing transmission of the vaccine serotypes to this population. It is also possible, however, that coincidental secular reductions in transmission of the vaccine serotypes may have contributed to this decline. Among HIV-infected individuals, in addition to the indirect associations of PCV, the increased availability of antiretroviral therapy could also have contributed to the observed reduction in IPD incidence, which may explain the tendency for the observed reduction in IPD to generally be higher than the model-predicted estimates, as well as the reduction in colonization and IPD due to nonvaccine serotypes (21) .
In children, we observed substantial replacement in nasopharyngeal colonization by nonvaccine pneumococcal serotypes, although there was a nonsignificant increase in non-vaccineserotype IPD. In the United Kingdom, despite an increase in non-vaccine-serotype colonization post-PCV, there was a net reduction in IPD incidence, and this was attributed to lower invasiveness of these serotypes (34) . In the United States, the incidence of IPD due to nonvaccine serotypes, particularly serotype 19A, increased by 58% among children aged less than 2 years and by 135% in children aged 2-4 years in the post-PCV7 period compared with the period before PCV7 introduction (35) . This was manifest as early as 3 years after PCV7 introduction (35, 36) . Similarly, in the United Kingdom, the incidence of serotype 19A IPD increased significantly following PCV7 vaccination of infants (34) . However, increases in IPD attributable to serotype 19A have also been described in unvaccinated communities (37) . In our population, transitioning from PCV7 to PCV13 (which includes serotype 19A as part of its formulation) within a short period of time may have prevented additional 19A invasive disease.
Limitations of our study include the absence of carriage data for HIV-infected children prior to the introduction of PCV in the national immunization program, so some analyses were limited to HIV-uninfected children. However, the rate of mother-to-child HIV transmission in South Africa is now under 3% (20) , and it will continue to fall with improvements in HIV care and treatment, further reducing the role of HIV in the IPD burden imposed on children. We did not analyze the changes in IPD due to PCV in HIV-exposed uninfected children, who may still remain at high risk of IPD (38) . Furthermore, our study did not have the statistical power to detect significant changes in IPD by individual vaccine serotype.
An inherent limitation of the model we evaluated is that some of the additional serotypes included in PCV13, especially serotypes 1 and 5, account for up to one-fifth of IPD cases in African children and are rarely identified as colonizing serotypes in otherwise healthy individuals (39, 40) . It is possible that the observed and model-predicted changes in IPD might differ more should there be an outbreak of disease from these serotypes, which are known to temporally fluctuate more than many of the other serotypes included in PCV13 and to cause epidemics of varying proportions (41) .
Our data show that changes in colonization in unvaccinated individuals following vaccine introduction can approximate IPD changes in the same population and can potentially be used in resource-limited settings to predict post-PCV-introduction changes in IPD, including those in HIV-infected populations.
